Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UI4L
|
|||
| Former ID |
DIB007912
|
|||
| Drug Name |
ND-0801
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 1/2 | [1] | |
| Company |
NeuroDerm Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nicotinic acetylcholine receptor (nAChR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01174355) A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD). U.S. National Institutes of Health. | |||
| REF 2 | Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table, 2013, Volume 27, Issue 4, 245-248. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.